{"content":"<li class=\"n-box-item date-title\" data-end=\"1490241599\" data-start=\"1490155200\" data-txt=\"Sunday, December 22, 2019\">Wednesday, March 22, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3252897\" data-ts=\"1490224410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYNO\" target=\"_blank\">CYNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252897-penn-national-gaming-headed-to-smallcap-600-shares-up-5_2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Penn National Gaming headed to SmallCap 600; shares up 5.2%</a></h4><ul>   <li>Penn National Gaming (<a href='https://seekingalpha.com/symbol/PENN' title='Penn National Gaming, Inc.'>PENN</a> <font color='red'>-1.8%</font>) is <font color='green'>up 5.2%</font> after hours on word that it will replace Cynosure (NASDAQ:<a href='https://seekingalpha.com/symbol/CYNO' title='Cynosure, Inc.'>CYNO</a>) in the S&amp;P SmallCap 600, now that Cynosure has been acquired by Hologic.</li>    <li>The move is effective before the open next Monday.</li>    <li>Penn National runs gaming and racing facilities and operates videogame terminals, with a focus on slot machines. It will be part of the Casinos and Gaming Sub-Industry Index.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252897\" data-linked=\"Penn National Gaming headed to SmallCap 600; shares up 5.2%\" data-tweet=\"$CYNO $CYNO $PENN - Penn National Gaming headed to SmallCap 600; shares up 5.2% https://seekingalpha.com/news/3252897-penn-national-gaming-headed-to-smallcap-600-shares-up-5_2?source=tweet\" data-url=\"https://seekingalpha.com/news/3252897-penn-national-gaming-headed-to-smallcap-600-shares-up-5_2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252895\" data-ts=\"1490223817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRWI\" target=\"_blank\">DRWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252895-dragonwaveplus-33-on-canadian-provider-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DragonWave +33% on Canadian provider contract</a></h4><ul>   <li>DragonWave (<a href='https://seekingalpha.com/symbol/DRWI' title='DragonWave Inc.'>DRWI</a> <font color='green'>+1.9%</font>) has <font color='green'>jumped 33.3%</font> after hours following word that Canadian provider Corridor Communication has <a href=\"https://seekingalpha.com/pr/16778929-cci-wireless-selects-dragonwave-harmony-enhanced-mc-network-upgrade\" target=\"_blank\">chosen to implement</a> its Harmony Enhanced MC backhaul offering.</li>    <li>That will boost capacity by more than threefold on the rural microwave network that CCI runs in Alberta.</li>    <li>The new radios replace existing DragonWave Horizon Compact radios, and offer the ability to deliver 1 Gbps uncompressed throughput in a single radio, and up to 2 Gbps per radio using the company's acceleration/compression features.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252895\" data-linked=\"DragonWave +33% on Canadian provider contract\" data-tweet=\"$DRWI - DragonWave +33% on Canadian provider contract https://seekingalpha.com/news/3252895-dragonwaveplus-33-on-canadian-provider-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3252895-dragonwaveplus-33-on-canadian-provider-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252881\" data-ts=\"1490218990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252881-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+47.0%</font>. <a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a> <font color='green'>+7.0%</font>. <a href='https://seekingalpha.com/symbol/PVH' title='PVH Corp.'>PVH</a> <font color='green'>+6.9%</font>. <a href='https://seekingalpha.com/symbol/MDRX' title='Allscripts Healthcare Solutions, Inc.'>MDRX</a> <font color='green'>+5.3%</font>. <a href='https://seekingalpha.com/symbol/MLHR' title='Herman Miller, Inc.'>MLHR</a> <font color='green'>+5.0%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='red'>-7.5%</font>. <a href='https://seekingalpha.com/symbol/DX' title='Dynex Capital Inc.'>DX</a> <font color='red'>-6.7%</font>. <a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a> <font color='red'>-6.6%</font>. <a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color='red'>-5.0%</font>. <a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a> <font color='red'>-5.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252881\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$HTGM $FIVE $PVH - After Hours Gainers / Losers https://seekingalpha.com/news/3252881-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3252881-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252880\" data-ts=\"1490218578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLHR\" target=\"_blank\">MLHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252880-herman-millerplus-5-profits-run-ahead-of-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herman Miller +5% as profits run ahead of expectations</a></h4><ul>   <li>Herman Miller (NASDAQ:<a href='https://seekingalpha.com/symbol/MLHR' title='Herman Miller, Inc.'>MLHR</a>) is trading <font color='green'>up 5%</font> postmarket after profits exceeded expectations in its <a href=\"https://seekingalpha.com/news/3252840-herman-miller-beats-0_07-misses-revenue\" target=\"_blank\">fiscal Q3 report</a> despite revenue that declined and missed, and amid strong profit guidance ahead.</li>    <li>New orders in Q3 were $543.2M (up 6.8% Y/Y). The company says a Feb. 6 price hike accelerated some $21M in orders that otherwise would have been entered in Q4; adjusting for that, it says net sales increased by 0.1% and orders rose by 4.8%.</li>    <li>It's in the early phases of executing on a cost-cutting plan, says CEO Brian Walker, with a target of $25M-$35M of annual savings over the next three fiscal years.</li>    <li>For Q4, it's expecting net sales of $575M-$595M (vs. consensus for $587.9M); that implies organic growth of 4.2% Y/Y at the midpoint. It's forecasting EPS of $0.53-$0.57, above consensus for $0.49.</li>    <li><a href=\"http://www.hermanmiller.com/about-us/investors.html\" target=\"_blank\">Conference call</a> to come tomorrow at 9:30 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16778833-herman-miller-reports-third-quarter-fiscal-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3252880\" data-linked=\"Herman Miller +5% as profits run ahead of expectations\" data-tweet=\"$MLHR - Herman Miller +5% as profits run ahead of expectations https://seekingalpha.com/news/3252880-herman-millerplus-5-profits-run-ahead-of-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3252880-herman-millerplus-5-profits-run-ahead-of-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252871\" data-ts=\"1490216781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVH\" target=\"_blank\">PVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252871-pvh-up-7-beats-in-q4-extends-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PVH up 7% as it beats in Q4, extends buyback</a></h4><ul>   <li>PVH Corp. (NYSE:<a href='https://seekingalpha.com/symbol/PVH' title='PVH Corp.'>PVH</a>) has <font color='green'>jumped 7%</font> in postmarket trading after posting <a href=\"https://seekingalpha.com/news/3252848-phillips-van-heusen-beats-0_04-beats-revenue\" target=\"_blank\">Q4 earnings</a> where it beat expectations thanks to international brand growth, and extended its buyback program.</li>    <li>EPS beat guidance, hitting $1.26 on a GAAP basis and $1.23 on non-GAAP.  &ldquo;We are very pleased with our fourth quarter results, which exceeded both our sales and earnings guidance despite the volatile macroeconomic environment and the highly promotional retail market in the U.S.,\" said CEO Emanuel Chirico.</li>    <li>The company also authorized a $750M increase in its stock repurchase program and stretched it to June 2020.</li>    <li>Revenue by segment: Calvin Klein NA, $409.4M (down 11%); Calvin Klein International, $385.5M (up 11.4%); Tommy Hilfiger NA, $419.1M (down 4.2%); Tommy Hilfiger International, $512.5M (up 9.9%); Heritage Brands Wholesale, $313.5M (down 6%); Heritage Brand Retail, $67.7M (down 1.7%).</li>    <li>For Q1, it's guiding to EPS of $0.73-$0.75 on a GAAP basis and $1.58-$1.60 on a non-GAAP basis (vs. consensus for $1.56). For the full year, it's forecasting $7.30-$7.40 non-GAAP vs. consensus for $7.26.</li>    <li><a href=\"http://edge.media-server.com/m/p/5d49x9rx/lan/en\" target=\"_blank\">Conference call</a> to come tomorrow at 9 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16778866-pvh-corp-reports-2016-fourth-quarter-full-year-results-provides-2017-guidance\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3252871\" data-linked=\"PVH up 7% as it beats in Q4, extends buyback\" data-tweet=\"$PVH - PVH up 7% as it beats in Q4, extends buyback https://seekingalpha.com/news/3252871-pvh-up-7-beats-in-q4-extends-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3252871-pvh-up-7-beats-in-q4-extends-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252868\" data-ts=\"1490216280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GST\" target=\"_blank\">GST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252868-gastar-exploration-to-buy-stack-oil-and-gas-leasehold-for-51m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gastar Exploration to buy STACK oil and gas leasehold for $51M</a></h4><ul>     <li>Gastar Exploration (NYSEMKT:<a href='https://seekingalpha.com/symbol/GST' title='Gastar Exploration Inc.'>GST</a>) <font color='green'>+3.7%</font>&nbsp;AH after <a href=\"https://seekingalpha.com/pr/16778860-gastar-exploration-announces-acquisition-stack-leasehold\" target=\"_blank\">agreeing to acquire</a> additional working and net revenue interests in 66 gross producing wells and 5,670 net acres of additional STACK oil and gas leasehold in Oklahoma.</li><li>GST says current  net production associated with the acquired  well interests is ~330 boe/day (49% oil), and 57% of the acreage is held-by-production.</li><li>GST says the $51M acquisition was funded through a tack-on issuance to funds managed by  Ares Management (NYSE:<a href='https://seekingalpha.com/symbol/ARES' title='Ares Management Corporation'>ARES</a>) of an additional $75M principal amount of GST's previously issued convertible notes due 2022.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252868\" data-linked=\"Gastar Exploration to buy STACK oil and gas leasehold for $51M\" data-tweet=\"$GST $GST $ARES - Gastar Exploration to buy STACK oil and gas leasehold for $51M https://seekingalpha.com/news/3252868-gastar-exploration-to-buy-stack-oil-and-gas-leasehold-for-51m?source=tweet\" data-url=\"https://seekingalpha.com/news/3252868-gastar-exploration-to-buy-stack-oil-and-gas-leasehold-for-51m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252867\" data-ts=\"1490216171\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTGM\" target=\"_blank\">HTGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252867-htgs-genetic-lung-cancer-test-ce-markd-shares-ahead-45-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HTG&#39;s genetic lung cancer test CE Mark&#39;d; shares ahead 45% after hours</a></h4><ul><li>Nano cap HTG Molecular Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a>) rockets&nbsp;<font color='green'>45%</font>&nbsp;after hours on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16778794-htg-molecular-diagnostics-obtains-ce-mark-htg-edgeseq-alkplus-assay-eu\" target=\"_blank\">announcement </a>that its <a href=\"https://www.htgmolecular.com/products/htg-edg-system-edgeseq\" target=\"_blank\">HTG EdgeSeq</a> ALK<em>Plus</em> Assay EU has received CE Mark certification.</li><li>The <em>in vitro</em> diagnostic assay measures mRNA ALK gene rearrangements in formalin-fixed, paraffin-embedded lung tumor samples from patients with previously diagnosed non-small cell lung cancer &#40;NSCLC&#41;. The assay may be used to help identify patients who are appropriate candidates for ALK-targeted therapeutics.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252867\" data-linked=\"HTG&#39;s genetic lung cancer test CE Mark&#39;d; shares ahead 45% after hours\" data-tweet=\"$HTGM - HTG&#39;s genetic lung cancer test CE Mark&#39;d; shares ahead 45% after hours https://seekingalpha.com/news/3252867-htgs-genetic-lung-cancer-test-ce-markd-shares-ahead-45-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3252867-htgs-genetic-lung-cancer-test-ce-markd-shares-ahead-45-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252866\" data-ts=\"1490216102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BEBE\" target=\"_blank\">BEBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252866-bebe-stores-exploring-strategic-alternativesplus-16-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bebe Stores exploring strategic alternatives; +16% after hours</a></h4><ul><li>Bebe Stores (<a href='https://seekingalpha.com/symbol/BEBE' title='bebe stores, inc.'>OTC:BEBE</a>) has retained B. Riley &amp; Co. for financial advising and a real estate advisor for assistance on options pertaining to lease holdings as its board&nbsp;<a href=\"https://seekingalpha.com/pr/16778878-bebe-stores-inc-exploring-strategic-alternatives\" target=\"_blank\">weighs strategic possibilities</a>.</li><li>Yesterday (March 21, 2017): <a href=\"https://seekingalpha.com/news/3252544-bebe-stores-minus-25-percent-said-close-stores-bid-stave-bankruptcy\" target=\"_blank\">Bebe Stores -25%, said to close stores in bid to stave off bankruptcy</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252866\" data-linked=\"Bebe Stores exploring strategic alternatives; +16% after hours\" data-tweet=\"$BEBE - Bebe Stores exploring strategic alternatives; +16% after hours https://seekingalpha.com/news/3252866-bebe-stores-exploring-strategic-alternativesplus-16-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3252866-bebe-stores-exploring-strategic-alternativesplus-16-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252858\" data-ts=\"1490214399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252858-five-below-up-6-store-growth-feeds-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Below up 6% as store growth feeds Q4 beat</a></h4><ul>   <li>Five Below (<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a> <font color='red'>-1.9%</font>) is <font color='green'>up 6%</font> after hours, making up today's decline and then some, after posting <a href=\"https://seekingalpha.com/news/3252832-five-beats-0_01-beats-revenue\" target=\"_blank\">Q4 earnings</a> where it beat on top and bottom lines as revenues and profits grew double digits on the back of store growth.</li>    <li>Operating income rose 17.1%, and net income rose 18.5% to $49.8M in Q4.</li>    <li>Revenues rose 19% and comparable sales rose 1%. The company opened a net five new stores, ending the quarter with 522 stores in 31 states (up 19.5% Y/Y).</li>    <li>For Q1, it's guiding to net sales of $228M-$232M, in line with expectations, assuming opening 26 new stores and flat to 2% growth in comp sales. EPS is forecast at $0.12-$0.14, vs. consensus for $0.14.</li>    <li>For the full year (which has a non-comp \"53rd week\" and when it targets 100 new stores), it's expecting sales of $1.21B-$1.23B and EPS of $1.55-$1.61.</li>    <li><a href=\"http://investor.fivebelow.com\" target=\"_blank\">Conference call</a> to come at 4:30 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16778791-five-inc-announces-fourth-quarter-fiscal-2016-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3252858\" data-linked=\"Five Below up 6% as store growth feeds Q4 beat\" data-tweet=\"$FIVE - Five Below up 6% as store growth feeds Q4 beat https://seekingalpha.com/news/3252858-five-below-up-6-store-growth-feeds-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3252858-five-below-up-6-store-growth-feeds-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252851\" data-ts=\"1490214038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALXN\" target=\"_blank\">ALXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252851-alexion-submits-soliris-marketing-application-in-japan-for-myasthenia-gravis-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexion submits Soliris marketing application in Japan for myasthenia gravis; shares up 1% after hours</a></h4><ul><li>Alexion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a>) <a href=\"https://seekingalpha.com/pr/16778817-alexion-submits-application-japan-soliris-eculizumab-potential-treatment-patients-refractory\" target=\"_blank\">files a marketing application</a> with the Japanese Ministry of Health, Labour and Welfare seeking approval of Soliris (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive (AChR-positive), an ultra-rare population. There are currently no approved therapies for the condition.</li><li>Patients with AChR-positive refractory gMG have difficulty walking, talking, swallowing and breathing. Exacerbations can be life-threatening and require hospitalization and intensive care.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252851\" data-linked=\"Alexion submits Soliris marketing application in Japan for myasthenia gravis; shares up 1% after hours\" data-tweet=\"$ALXN - Alexion submits Soliris marketing application in Japan for myasthenia gravis; shares up 1% after hours https://seekingalpha.com/news/3252851-alexion-submits-soliris-marketing-application-in-japan-for-myasthenia-gravis-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3252851-alexion-submits-soliris-marketing-application-in-japan-for-myasthenia-gravis-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252848\" data-ts=\"1490213867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVH\" target=\"_blank\">PVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252848-phillips-van-heusen-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phillips-Van Heusen beats by $0.04, beats on revenue</a></h4><ul><li>Phillips-Van Heusen (NYSE:<a href='https://seekingalpha.com/symbol/PVH' title='PVH Corp.'>PVH</a>): Q4 EPS of $1.23 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $2.1B (-0.5% Y/Y) <font color='green'>beats by $10M</font>.</li><li>Shares <font color='green'>+6.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16778866-pvh-corp-reports-2016-fourth-quarter-full-year-results-provides-2017-guidance'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252848\" data-linked=\"Phillips-Van Heusen beats by $0.04, beats on revenue\" data-tweet=\"$PVH - Phillips-Van Heusen beats by $0.04, beats on revenue https://seekingalpha.com/news/3252848-phillips-van-heusen-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3252848-phillips-van-heusen-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252847\" data-ts=\"1490213719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMH\" target=\"_blank\">AMH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252847-american-homes-4-rentminus-1_5-on-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Homes 4 Rent -1.5% on share sale</a></h4><ul><li>The company <a href=\"https://seekingalpha.com/pr/16778845-american-homes-4-rent-announces-public-offering-common-shares\" target=\"_blank\">is selling 11M shares</a>, with underwriter greenshoe for another 1.65M shares. Alongside, Chairman Wayne Hughes will purchase $50M of company stock in a private placement at the offering price.</li><li>Proceeds will be used to help repay in full <a href='https://seekingalpha.com/symbol/AMH' title='American Homes 4 Rent'>AMH</a>'s 2014-SFR1 securitization loan, which had a balance of $456.1M as of Dec. 31.</li><li>Shares&nbsp;<font color='red'>-1.5%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3252847\" data-linked=\"American Homes 4 Rent -1.5% on share sale\" data-tweet=\"$AMH - American Homes 4 Rent -1.5% on share sale https://seekingalpha.com/news/3252847-american-homes-4-rentminus-1_5-on-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3252847-american-homes-4-rentminus-1_5-on-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252843\" data-ts=\"1490213400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTBX\" target=\"_blank\">HTBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252843-heat-biologics-readies-equity-offering-shares-slip-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heat Biologics readies equity offering; shares slip 6% after hours</a></h4><ul><li>Heat Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a>) <a href=\"https://seekingalpha.com/pr/16778802-heat-biologics-announces-proposed-public-offering-common-stock\" target=\"_blank\">initiates </a>a public offering of common stock. Price, volume and terms have yet to be announced. Shares are down&nbsp;<font color='red'>6%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252843\" data-linked=\"Heat Biologics readies equity offering; shares slip 6% after hours\" data-tweet=\"$HTBX - Heat Biologics readies equity offering; shares slip 6% after hours https://seekingalpha.com/news/3252843-heat-biologics-readies-equity-offering-shares-slip-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3252843-heat-biologics-readies-equity-offering-shares-slip-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252835\" data-ts=\"1490213145\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLCM\" target=\"_blank\">BLCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252835-bellicum-pharma-launches-5m-share-equity-offering-shares-slip-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bellicum Pharma launches 5M-share equity offering; shares slip 3% after hours</a></h4><ul><li>Bellicum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a>) <a href=\"https://seekingalpha.com/pr/16778799-bellicum-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences </a>a public offering of 5M shares of common stock. Underwriters over-allotment is an additional 750K shares. Price and terms have yet to be announced.</li><li>Today's close was $14.35.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;after hours on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252835\" data-linked=\"Bellicum Pharma launches 5M-share equity offering; shares slip 3% after hours\" data-tweet=\"$BLCM - Bellicum Pharma launches 5M-share equity offering; shares slip 3% after hours https://seekingalpha.com/news/3252835-bellicum-pharma-launches-5m-share-equity-offering-shares-slip-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3252835-bellicum-pharma-launches-5m-share-equity-offering-shares-slip-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252832\" data-ts=\"1490212951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252832-five-below-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Below beats by $0.01, beats on revenue</a></h4><ul><li>Five Below (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a>): Q4 EPS of $0.90 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $388.1M (+18.9% Y/Y) <font color='green'>beats by $0.47M</font>.</li><li>Shares <font color='green'>+3.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16778791-five-inc-announces-fourth-quarter-fiscal-2016-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252832\" data-linked=\"Five Below beats by $0.01, beats on revenue\" data-tweet=\"$FIVE - Five Below beats by $0.01, beats on revenue https://seekingalpha.com/news/3252832-five-below-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3252832-five-below-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252826\" data-ts=\"1490211873\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DYN\" target=\"_blank\">DYN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252826-dynegyminus-6-bill-to-help-dominion-plant-advances-in-connecticut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dynegy -6% as bill to help Dominion plant advances in Connecticut</a></h4><ul><li>Dynegy (<a href='https://seekingalpha.com/symbol/DYN' title='Dynegy Inc.'>DYN</a> <font color='red'>-6.1%</font>) declines as much as 6.6% to a record low $6.81 in intraday trading, as investors worry that New England plants the company wants to sell now may fetch lower  prices after <a href=\"http://www.nhregister.com/business/20170321/millstone-bill-heads-to-full-connecticut-legislature\" target=\"_blank\">Connecticut's legislature passed</a> a bill to aid Dominion&rsquo;s (<a href='https://seekingalpha.com/symbol/D' title='Dominion Energy, Inc.'>D</a> <font color='green'>+0.6%</font>) Millstone  nuclear plant.</li><li>A bill allowing Millstone to bid into Connecticut auctions for renewable energy passed a key state House committee yesterday and now moves to the state Senate.</li><li>Source: Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3252826\" data-linked=\"Dynegy -6% as bill to help Dominion plant advances in Connecticut\" data-tweet=\"$DYN $DYN $D - Dynegy -6% as bill to help Dominion plant advances in Connecticut https://seekingalpha.com/news/3252826-dynegyminus-6-bill-to-help-dominion-plant-advances-in-connecticut?source=tweet\" data-url=\"https://seekingalpha.com/news/3252826-dynegyminus-6-bill-to-help-dominion-plant-advances-in-connecticut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252824\" data-ts=\"1490211581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAZZ\" target=\"_blank\">JAZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252824-jazz-pharma-loses-challenge-to-xyrem-patent-covering-distribution-system-shares-slip-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jazz Pharma loses challenge to Xyrem patent covering distribution system; shares slip 1%</a></h4><ul><li>In an inter partes review proceeding, the Patent Trial and Appeal Board &#40;PTAB&#41; rules that three claims of Jazz Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/JAZZ' title='Jazz Pharmaceuticals, Inc.'>JAZZ</a> <font color='red'>-0.9%</font>) <a href=\"https://www.google.com/patents/US8731963\" target=\"_blank\">U.S. Patent No. 8,731,963</a>&nbsp;are invalid as obvious. The patent covers a drug distribution system and method that utilizes a central pharmacy and database to track all prescriptions for a sensitive drug such as narcolepsy med <a href=\"https://www.xyrem.com/\" target=\"_blank\">Xyrem </a>(sodium oxybate).</li><li>Other patents covering Xyrem were invalidated in July 2016.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3252824\" data-linked=\"Jazz Pharma loses challenge to Xyrem patent covering distribution system; shares slip 1%\" data-tweet=\"$JAZZ - Jazz Pharma loses challenge to Xyrem patent covering distribution system; shares slip 1% https://seekingalpha.com/news/3252824-jazz-pharma-loses-challenge-to-xyrem-patent-covering-distribution-system-shares-slip-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3252824-jazz-pharma-loses-challenge-to-xyrem-patent-covering-distribution-system-shares-slip-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252822\" data-ts=\"1490210600\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252822-petrobras-upgraded-credit-suisse-following-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras upgraded at Credit Suisse following Q4 results</a></h4><ul><li>Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color='green'>+3.2%</font>) is <a href=\"http://blogs.barrons.com/emergingmarketsdaily/2017/03/22/petrobras-has-20-upside-cs-upgrade-says/\" target=\"_blank\">upgraded</a> to Outperform from Neutral with an $11 price target at Credit Suisse following the stock's recent selloff due to oil price weakness and Brazil's regulatory request to restate filings to reflect currency hedges.</li><li>Credit Suisse says PBR's <a href=\"https://seekingalpha.com/news/3252624-petrobras-reports-q4-profit-20-percent-lower-debt-load\" target=\"_blank\">Q4 net income</a> came in below its estimates but $19.8B in capital spending this year is &ldquo;above market expectations&rdquo; and the company generated positive free cash flow after interest payments.</li><li>The firm also notes leverage measured as net debt/EBITDA fell to 3.8x from 4.5x in Q3, which it says reinforces the view that net debt/EBITDA may reach the company&rsquo;s 2.5x target before year-end 2018.</li><li>But Credit Suisse warns that PBR&rsquo;s leverage to oil is higher than most peers, and if oil prices deteriorate further in the short term, the company&rsquo;s equity could sharply and negatively react, even if long-term oil fundamentals remain the same.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252822\" data-linked=\"Petrobras upgraded at Credit Suisse following Q4 results\" data-tweet=\"$PBR - Petrobras upgraded at Credit Suisse following Q4 results https://seekingalpha.com/news/3252822-petrobras-upgraded-credit-suisse-following-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3252822-petrobras-upgraded-credit-suisse-following-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252819\" data-ts=\"1490209376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252819-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corp.'>CPSH</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/BOSC' title='B.O.S. Better Online Solutions'>BOSC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/VLTC' title='Voltari Corporation'>OTC:VLTC</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252819\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$CPSH $PRKR $AAOI - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3252819-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252819-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252812\" data-ts=\"1490207853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252812-sears-seeks-to-calm-investors-explaining-going-concern-language\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears seeks to calm investors by explaining (?) &quot;going concern&quot; language</a></h4><ul>     <li>Sears (SHLD <font color='red'>-14.2%</font>) remains nearly 15% lower after CFO&nbsp;Jason Hollar attempts to <a href=\"http://www.cnbc.com/2017/03/21/sears-flags-going-concern-doubts.html\" target=\"_blank\">ease investor fears</a> by  soft-pedaling the language in its latest 10-K on <a href=\"https://seekingalpha.com/news/3252609-sears-annual-report-notes-substantial-going-concern-doubt\" target=\"_blank\">\"substantial\" going-concern doubt</a>.</li>     <li>In a <a href=\"http://blog.searsholdings.com/shc-updates/sears-holdings-remains-focused-on-long-term-profitability/\" target=\"_blank\">blog post</a> this afternoon, the CFO said the inclusion of the new language was meant to adhere to regulatory standards.</li>     <li>SHLD's independent auditor, Deloitte, made <a href=\"http://www.marketwatch.com/story/why-sears-but-not-its-auditor-gave-a-going-concern-warning-2017-03-22\" target=\"_blank\">no mention of the going concern issue</a> in its annual report audit opinion, but Hollar offers the somewhat circular explanation that its independent auditors provided the company with an \"unqualified audit opinion,\" which the CFO then says means SHLD \"remains a 'going concern.'\"</li><li>Debtwire legal analyst Joshua Friedman speculates the new language could be a signal that CEO&nbsp;Eddie Lampert, who has injected cash into SHLD from his ESL&nbsp;Investments hedge fund and owns some of the company's unsecured debt, could be ready to turn off the financial spigot.</li>           </ul><div class=\"tiny-share-widget\" data-id=\"3252812\" data-linked=\"Sears seeks to calm investors by explaining (?) &quot;going concern&quot; language\" data-tweet=\"$SHLDQ - Sears seeks to calm investors by explaining (?) &quot;going concern&quot; language https://seekingalpha.com/news/3252812-sears-seeks-to-calm-investors-explaining-going-concern-language?source=tweet\" data-url=\"https://seekingalpha.com/news/3252812-sears-seeks-to-calm-investors-explaining-going-concern-language\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252811\" data-ts=\"1490207452\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATU\" target=\"_blank\">ATU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252811-actuants-updates-fq3-and-2017-guidance-sharesminus-4_25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Actuant&#39;s updates FQ3 and 2017 guidance; shares -4.25%</a></h4><ul>     <li>Actuant (NYSE:<a href='https://seekingalpha.com/symbol/ATU' title='Actuant Corporation'>ATU</a>) <a href=\"https://seekingalpha.com/pr/16777984-actuant-reports-second-quarter-results-updates-fiscal-2017-guidance\" target=\"_blank\">expects</a> FQ3 sales of $290-$300M and EPS of $0.38 -$0.48 vs. a consensus of $298.4M and EPS of $0.42.</li>     <li>The company estimates full year revenue of $1.075-$1.125B and EPS of $1.1-1.20 vs. consensus of $1.09B and $1.13.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252698-actuant-misses-0_01-beats-revenue\" target=\"_blank\">Actuant misses by $0.01, beats on revenue</a> (March 22).</li><li>Shares&nbsp;<font color='red'>-4.25%</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3252811\" data-linked=\"Actuant&#39;s updates FQ3 and 2017 guidance; shares -4.25%\" data-tweet=\"$ATU $EPAC - Actuant&#39;s updates FQ3 and 2017 guidance; shares -4.25% https://seekingalpha.com/news/3252811-actuants-updates-fq3-and-2017-guidance-sharesminus-4_25?source=tweet\" data-url=\"https://seekingalpha.com/news/3252811-actuants-updates-fq3-and-2017-guidance-sharesminus-4_25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252809\" data-ts=\"1490206493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ING\" target=\"_blank\">ING</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252809-ing-criminal-probe-touching-on-vimpelcom-uzbek-transactions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ING criminal probe touching on VimpelCom/Uzbek transactions</a></h4><ul>   <li>A <a href=\"https://seekingalpha.com/news/3252647-ing-says-significant-fines-possible\" target=\"_blank\">probe into the Netherlands' ING Groep</a> (NYSE:<a href='https://seekingalpha.com/symbol/ING' title='ING Groep N.V.'>ING</a>) that could result in \"significant\" fines for the financial services company is touching on VimpelCom's (<a href=\"https://seekingalpha.com/symbol/VIP\" target=\"_blank\">VIP</a> <font color='red'>-1.4%</font>) <a href=\"http://www.nasdaq.com/article/ing-investigation-includes-uzbek-transactions-by-vimpelcom-prosecutors-20170322-00277\" target=\"_blank\">scandal over Uzbekistan</a>.</li>    <li>The corruption investigation is tackling past \"irregular transactions\" between the telecom and Uzbek officials, transactions that led to a multinational probe of VimpelCom -- which <a href=\"https://seekingalpha.com/news/3120656-vimpelcom-announces-settlements-u-s-netherlands-paying-795m\" target=\"_blank\">agreed to a settlement of $795M</a> with officials in the U.S. and the Netherlands.</li>    <li>The bank is \"suspected of having enabled international corruption and money laundering,\" Dutch prosecutors say.</li>    <li><a href='https://seekingalpha.com/symbol/ING' title='ING Groep N.V.'>ING</a> is off lows but still <font color='red'>down 3.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252809\" data-linked=\"ING criminal probe touching on VimpelCom/Uzbek transactions\" data-tweet=\"$ING $ING $VEON - ING criminal probe touching on VimpelCom/Uzbek transactions https://seekingalpha.com/news/3252809-ing-criminal-probe-touching-on-vimpelcom-uzbek-transactions?source=tweet\" data-url=\"https://seekingalpha.com/news/3252809-ing-criminal-probe-touching-on-vimpelcom-uzbek-transactions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252806\" data-ts=\"1490205663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252806-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TELL' title='Tellurian Inc.'>TELL</a> <font color='green'>+9%</font>. SLW <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SXCP' title='SunCoke Energy Partners'>SXCP</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/EPE' title='EP Energy Corporation'>EPE</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/MCEP' title='Mid-Con Energy Partners'>MCEP</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PES' title='Pioneer Energy Services'>PES</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252806\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$TELL $WPM $SXCP - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3252806-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252806-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252803\" data-ts=\"1490204599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252803-natural-gas-eases-on-forecasts-for-warmer-temps\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas eases on forecasts for warmer temps</a></h4><ul><li>The calendar says spring, but winter continues in full force in March in the Northeast. Nevertheless, markets look ahead, and forecasts for the remainder of the month are looking somewhat more benign than the first three weeks.</li><li>The news is giving satiated bulls an excuse to take some profits, with natural gas today&nbsp;<font color='red'>down 2%</font>. It's still&nbsp;<font color='green'>higher by more than 10%</font>&nbsp;for the month.</li><li><a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>&nbsp;<font color='red'>-1.4%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>, <a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3252803\" data-linked=\"Natural gas eases on forecasts for warmer temps\" data-tweet=\"$UNG $UGAZ $DGAZ - Natural gas eases on forecasts for warmer temps https://seekingalpha.com/news/3252803-natural-gas-eases-on-forecasts-for-warmer-temps?source=tweet\" data-url=\"https://seekingalpha.com/news/3252803-natural-gas-eases-on-forecasts-for-warmer-temps\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252798\" data-ts=\"1490202391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNK\" target=\"_blank\">CNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252798-cinemarkminus-2_2-wunderlich-cuts-runs-out-of-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cinemark -2.2%; Wunderlich cuts as it runs out of upside</a></h4><ul>   <li>Cinemark (NYSE:<a href='https://seekingalpha.com/symbol/CNK' title='Cinemark Holdings, Inc'>CNK</a>) is <font color='red'>2.2% lower</font>, coming off yesterday's 52-week high of $44.84, as Wunderlich downgrades to Hold on valuation issues.</li>    <li>Analyst Matt Harrigan reiterated a $47 price target, meaning there's less upside in the stock than before, Bloomberg notes.</li>    <li>He expects favorable presentations from studios at CinemaCon next week in Las Vegas, and isn't overly concerned about immediate effects from the studios' talks about narrowing exhibitor release windows by offering films for home viewing earlier.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252798\" data-linked=\"Cinemark -2.2%; Wunderlich cuts as it runs out of upside\" data-tweet=\"$CNK - Cinemark -2.2%; Wunderlich cuts as it runs out of upside https://seekingalpha.com/news/3252798-cinemarkminus-2_2-wunderlich-cuts-runs-out-of-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3252798-cinemarkminus-2_2-wunderlich-cuts-runs-out-of-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252794\" data-ts=\"1490200825\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252794-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+27%</font>. CLNT <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/INNL' title='Innocoll'>INNL</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ALBO' title='Albireo Pharma, Inc.'>ALBO</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+9%</font>.</li><li><b>Losers:&nbsp;</b><a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a> <font color='red'>-20%</font>. SHLD <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/GLA' title='GlassBridge Enterprises, Inc.'>GLA</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BOSC' title='B.O.S. Better Online Solutions'>BOSC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc'>LGCY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/BIOA' title='BioAmber'>OTC:BIOA</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252794\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MBRX $SEII $INNL - Midday Gainers / Losers https://seekingalpha.com/news/3252794-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3252794-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252793\" data-ts=\"1490200699\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252793-buy-urban-outfitters-and-sell-l-brands-keybanc-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buy Urban Outfitters and sell L Brands, KeyBanc says</a></h4><ul>     <li>Mall-based retailers are <a href=\"https://seekingalpha.com/news/3252777-another-rough-session-retail-reits-keybanc-downgrades-sears-warns\" target=\"_blank\">taking a beating</a>, but Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='red'>-1.1%</font>) is down by less than most after KeyBanc <a href=\"https://www.streetinsider.com/Analyst+Comments/KeyBanc+Upgrades+Urban+Outfitters%2C+Inc.+%28URBN%29+to+Overweight/12692870.html\" target=\"_blank\">upgrades</a> shares to Overweight from Sector Weight, citing URBN's highly differentiated product offering and significant investments to capture e-commerce share.</li>     <li>KeyBanc thinks URBN is smartly positioning itself for an even split between e-commerce and stores over the next 3-4 years, with e-commerce already ~20% of sales for both Urban Outfitters and Anthropologie, and at 50% for Free People.</li>     <li>The firm also believes URBN&rsquo;s more affluent and style-focused target market lends itself well to the e-commerce environment.</li>     <li>On the flip side, L&nbsp;Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color='red'>-2.8%</font>) is <a href=\"http://thefly.com/landingPageNews.php?id=2523703&amp;headline=URBN;LB-Battleground-Retail-analysts-conflicted-on-Urban-Outfitters-L-Brands\" target=\"_blank\">downgraded</a> to Underweight from Sector Weight with a $40 price target to reflect both high C-mall exposure and emerging headwinds in its Victoria  Secret and Bath and Body Works brands.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252793\" data-linked=\"Buy Urban Outfitters and sell L Brands, KeyBanc says\" data-tweet=\"$URBN $URBN $LB - Buy Urban Outfitters and sell L Brands, KeyBanc says https://seekingalpha.com/news/3252793-buy-urban-outfitters-and-sell-l-brands-keybanc-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3252793-buy-urban-outfitters-and-sell-l-brands-keybanc-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252788\" data-ts=\"1490199968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BDX\" target=\"_blank\">BDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252788-supreme-court-declines-to-review-retractable-techs-litigation-against-bd-case-remanded-to\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Supreme Court declines to review Retractable Tech&#39;s litigation against BD, case remanded to Texas district court for redetermination of damages; BD up 1%</a></h4><ul><li>Becton, Dickinson and Company (<a href='https://seekingalpha.com/symbol/BDX' title='Becton, Dickinson and Company'>BDX</a> <font color='green'>+1%</font>) perks up light volume on the news that the U.S. Supreme Court has <a href=\"https://seekingalpha.com/pr/16777481-retractable-technologies-inc-announces-litigation-updates\" target=\"_blank\">declined to review</a> a December 2016 Appeals Court decision that remanded its litigation with Retractable Technologies (<a href='https://seekingalpha.com/symbol/RVP' title='Retractable Technologies, Inc'>RVP</a> <font color='red'>-0.9%</font>) to the district level in Texas.</li><li>In December, an appeals court overturned a September 2013 jury verdict of $113.5M in favor of Retractable who accused BD of trying to monopolize the safety syringe market.</li><li>The case will go back to the Texas court to redetermine the amount of damages entitled to Retractable. Under antitrust law, any award will be trebled.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3228591-becton-dickinson-prevails-appeal-antitrust-suit\" target=\"_blank\">Becton, Dickinson prevails in appeal of antitrust suit</a> (Dec. 5, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252788\" data-linked=\"Supreme Court declines to review Retractable Tech&#39;s litigation against BD, case remanded to Texas district court for redetermination of damages; BD up 1%\" data-tweet=\"$BDX $BDX $RVP - Supreme Court declines to review Retractable Tech&#39;s litigation against BD, case remanded to Texas district court for redetermination of damages; BD up 1% https://seekingalpha.com/news/3252788-supreme-court-declines-to-review-retractable-techs-litigation-against-bd-case-remanded-to?source=tweet\" data-url=\"https://seekingalpha.com/news/3252788-supreme-court-declines-to-review-retractable-techs-litigation-against-bd-case-remanded-to\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252789\" data-ts=\"1490199743\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDG\" target=\"_blank\">TDG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252789-transdigm-downgraded-cowen-amid-potential-for-government-probe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransDigm downgraded at Cowen amid potential for government probe</a></h4><ul>     <li>TransDigm (<a href='https://seekingalpha.com/symbol/TDG' title='TransDigm Group Incorporated'>TDG</a> <font color='red'>-4.2%</font>) is <a href=\"https://twitter.com/thenotablecalls/status/844543359884673024\" target=\"_blank\">downgraded</a> to Market Perform from Outperform with a $219 price target, cut from $270, at Cowen, potentially the start of another round of bearish brokerage attention after a California congressman <a href=\"https://seekingalpha.com/news/3252540-transdigm-nearly-another-10-percent-call-government-probe\" target=\"_blank\">asked for an investigation</a> into the company's business practices.</li><li>Cowen analysts say the U.S. Department of Defense is <a href=\"https://twitter.com/thenotablecalls/status/844543493687164932\" target=\"_blank\">not likely to issue a clean bill of health</a> for business with TDG before an investigation concludes, so the stock has more potential to decline before it recovers.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252789\" data-linked=\"TransDigm downgraded at Cowen amid potential for government probe\" data-tweet=\"$TDG - TransDigm downgraded at Cowen amid potential for government probe https://seekingalpha.com/news/3252789-transdigm-downgraded-cowen-amid-potential-for-government-probe?source=tweet\" data-url=\"https://seekingalpha.com/news/3252789-transdigm-downgraded-cowen-amid-potential-for-government-probe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252787\" data-ts=\"1490198511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252787-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252787\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$WGO $WKHS $XELB - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3252787-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3252787-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252784\" data-ts=\"1490198211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252784-searsminus-15-after-going-concern-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears -15% after &#39;going concern&#39; warning</a></h4><ul><li>A&nbsp;<font color='red'>15% decline</font>&nbsp;in the price of Sears Holdings (SHLD) as well as <a href=\"https://seekingalpha.com/news/3252777-another-rough-session-retail-reits-keybanc-downgrades-sears-warns\" target=\"_blank\">big drops in a</a> number of mall REITs suggests Sears' \"going concern\" <a href=\"https://seekingalpha.com/news/3252609-sears-annual-report-notes-substantial-going-concern-doubt\" target=\"_blank\">warning in its 10-K</a> was at least somewhat of a surprise (though one might have expected otherwise).</li><li>Also lower is Seritage Holdings (<a href='https://seekingalpha.com/symbol/SRG' title='Seritage Growth Properties'>SRG</a> <font color='red'>-1.7%</font>), for whom Sears is its top tenant.</li><li>Credit Suisse's Seth Sigman<a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/03/22/sears-tells-us-what-many-already-knew-here-are-winners-and-losers/?mod=BOL_hp_blog_stw\" target=\"_blank\"> looks for winners</a>, and finds two in Home Depot (<a href='https://seekingalpha.com/symbol/HD' title='Home Depot, Inc.'>HD</a> <font color='green'>+0.6%</font>) and Lowe's (<a href='https://seekingalpha.com/symbol/LOW' title='Lowe&#39;s Companies, Inc.'>LOW</a> <font color='green'>+0.8%</font>). Sears, he notes, still has 15-20% of the appliance market and 10-15% of the tool market. Continued declines in sales at Sears could contribute 50 basis points or more to comps at HD and LOW.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252784\" data-linked=\"Sears -15% after &#39;going concern&#39; warning\" data-tweet=\"$SHLDQ $SHLDQ $SRG - Sears -15% after &#39;going concern&#39; warning https://seekingalpha.com/news/3252784-searsminus-15-after-going-concern-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3252784-searsminus-15-after-going-concern-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252777\" data-ts=\"1490197021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBL\" target=\"_blank\">CBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252777-another-rough-session-for-retail-reits-keybanc-downgrades-sears-warns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Another rough session for retail REITs as KeyBanc downgrades, Sears warns</a></h4><ul><li>KeyBanc throws in the towel on the mall/shopping center sector, downgrading to Sector Weight. Hardest hit is CBL &amp; Associates (<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a> <font color='red'>-5.3%</font>) which is downgraded to Sector Weight from Overweight as the team there sees the most risk to mid-quality malls.</li><li>Then there's Sears, and <a href=\"https://seekingalpha.com/news/3252609-sears-annual-report-notes-substantial-going-concern-doubt\" target=\"_blank\">its 10-K last night</a> warned of \"going concern\" issues.</li><li>Simon Property (<a href='https://seekingalpha.com/symbol/SPG' title='Simon Property Group, Inc.'>SPG</a> <font color='red'>-2.7%</font>), General Growth (GGP <font color='red'>-2.8%</font>), Macerich (<a href='https://seekingalpha.com/symbol/MAC' title='Macerich Co.'>MAC</a> <font color='red'>-2.6%</font>), PREIT (<a href='https://seekingalpha.com/symbol/PEI' title='Pennsylvania Real Estate Investment Trust'>PEI</a> <font color='red'>-4.6%</font>), Kimco (<a href='https://seekingalpha.com/symbol/KIM' title='Kimco Realty Corporation'>KIM</a> <font color='red'>-2.7%</font>), Retail Opportunity (<a href='https://seekingalpha.com/symbol/ROIC' title='Retail Opportunity Investments Corp.'>ROIC</a> <font color='red'>-2.4%</font>), DDR (DDR <font color='red'>-3.3%</font>), Tanger Factory (<a href='https://seekingalpha.com/symbol/SKT' title='Tanger Factory Outlet Centers, Inc.'>SKT</a> <font color='red'>-2.6%</font>), Taubman (<a href='https://seekingalpha.com/symbol/TCO' title='Taubman Centers, Inc.'>TCO</a> <font color='red'>-2.9%</font>), Brixmor (<a href='https://seekingalpha.com/symbol/BRX' title='Brixmor Property Group Inc.'>BRX</a> <font color='red'>-3.2%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3252777\" data-linked=\"Another rough session for retail REITs as KeyBanc downgrades, Sears warns\" data-tweet=\"$CBL $CBL $SPG - Another rough session for retail REITs as KeyBanc downgrades, Sears warns https://seekingalpha.com/news/3252777-another-rough-session-for-retail-reits-keybanc-downgrades-sears-warns?source=tweet\" data-url=\"https://seekingalpha.com/news/3252777-another-rough-session-for-retail-reits-keybanc-downgrades-sears-warns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252776\" data-ts=\"1490196880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252776-eros-internationalminus-6_4-film-delay-stirs-liquidity-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros International -6.4% as film delay stirs liquidity talk</a></h4><ul>   <li>Indian film producer Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) is <font color='red'>off 6.4%</font> as bearish investors raise new liquidity questions around the postponement of <i>Sarkar 3,</i> a high-profile film fronted by Bollywood legend Amitabh Bachchan.</li>    <li>The sequel was set to release April 7, and has been delayed to May 12. A <a href=\"http://www.catchnews.com/bollywood-news/is-sarkar-3-postponed-because-of-eros-strangely-krk-has-the-answer-55266.html\" target=\"_blank\">Web report</a> attributes the move to a cash crunch at Eros: &ldquo;According to sources #sarkar3 can't release on 7th April coz Eros is not paying balance 23Cr to producers\" -- 23 crore in rupees, or about $3.5M.</li>    <li>In a <a href=\"https://twitter.com/ErosNow/status/844211772017979392\" target=\"_blank\">tweet</a>, Eros has said the postponement was a mutual decision between themselves, Bachchan, director/producer Ram Gopal Varma and Save.</li>    <li>Share volume is heavy on the NYSE, about to surpass standard full-day volume of 339,800 shares this morning.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252776\" data-linked=\"Eros International -6.4% as film delay stirs liquidity talk\" data-tweet=\"$EROS - Eros International -6.4% as film delay stirs liquidity talk https://seekingalpha.com/news/3252776-eros-internationalminus-6_4-film-delay-stirs-liquidity-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3252776-eros-internationalminus-6_4-film-delay-stirs-liquidity-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252768\" data-ts=\"1490194888\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252768-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/INNL' title='Innocoll'>INNL</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color='green'>+11%</font>. SSH <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PHMD' title='PhotoMedex, Inc.'>PHMD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252768\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$MBRX $INNL $IDRA - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3252768-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3252768-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252764\" data-ts=\"1490194651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RUN\" target=\"_blank\">RUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252764-sunrun-upgraded-to-buy-ubs-on-accelerating-prospects-out-of-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sunrun upgraded to Buy at UBS on accelerating prospects out of Q4</a></h4><ul><li>Sunrun (<a href='https://seekingalpha.com/symbol/RUN' title='Sunrun'>RUN</a> <font color='green'>+2.9%</font>) <a href=\"https://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+Sunrun+%28RUN%29+to+Buy%2C+%22accelerating+prospects+out+of+4Q%3B+gives+us+confidence%22/12694248.html\" target=\"_blank\">upgraded to Buy</a> from Neutral with a $6.50 price target at UBS, which sees pitfalls associated with Q4 now in the past and the company poised to execute as the story heads  towards northeastern states.</li><li>The firm sees the National Grid deal as substantially more meaningful than investors are willing to acknowledge, and views RUN's accelerated hiring as epitomizing its relative confidence.</li><li>With Tesla's SolarCity subsidiary and others stuck on execution, UBS sees the opportunity for RUN to reset already low expectations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252764\" data-linked=\"Sunrun upgraded to Buy at UBS on accelerating prospects out of Q4\" data-tweet=\"$RUN - Sunrun upgraded to Buy at UBS on accelerating prospects out of Q4 https://seekingalpha.com/news/3252764-sunrun-upgraded-to-buy-ubs-on-accelerating-prospects-out-of-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3252764-sunrun-upgraded-to-buy-ubs-on-accelerating-prospects-out-of-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252761\" data-ts=\"1490193250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAL\" target=\"_blank\">AAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252761-bloomberg-american-air-in-advanced-talks-to-buy-china-southern-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: American Air in advanced talks to buy China Southern stake</a></h4><ul>     <li>American Airlines (<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a> <font color='red'>-2.5%</font>) is <a href=\"https://www.bloomberg.com/news/articles/2017-03-22/american-air-said-in-advanced-talks-to-buy-china-southern-stake\" target=\"_blank\">in advanced talks</a> to acquire a stake in China Southern Airlines (<a href='https://seekingalpha.com/symbol/ZNH' title='China Southern Airlines Company Limited'>ZNH</a>), Bloomberg reports.</li>     <li>The negotiations focus on a ~$200M investment in China Southern&rsquo;s Hong Kong-listed shares, likely through a private placement, according to the report.</li>     <li>An investment in China Southern would allow AAL to strengthen its presence in a market that the IATA predicts will surpass the U.S. to become the world&rsquo;s biggest in terms of passenger numbers by 2024.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252761\" data-linked=\"Bloomberg: American Air in advanced talks to buy China Southern stake\" data-tweet=\"$AAL $AAL $ZNH - Bloomberg: American Air in advanced talks to buy China Southern stake https://seekingalpha.com/news/3252761-bloomberg-american-air-in-advanced-talks-to-buy-china-southern-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3252761-bloomberg-american-air-in-advanced-talks-to-buy-china-southern-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252759\" data-ts=\"1490193059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252759-crude-futures-decline-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures decline further post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>:Crude <strong>+5.0M</strong> barrels vs. +2.8M consensus, -0.24M last week.</li><li>Gasoline <strong>-2.8M </strong>barrels vs. -2.0M consensus, -3.06M last week.</li><li>Distillates <strong>-1.9M</strong> vs. -1.39M consensus, -4.23M last week.</li><li>Futures&nbsp;<font color='red'>-1.55%</font>&nbsp;to $47.49.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3252759\" data-linked=\"Crude futures decline further post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures decline further post inventory data https://seekingalpha.com/news/3252759-crude-futures-decline-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3252759-crude-futures-decline-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252756\" data-ts=\"1490192407\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADAP\" target=\"_blank\">ADAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252756-adaptimmune-prices-equity-offering-4_20-shares-off-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adaptimmune prices equity offering at $4.20; shares off 5%</a></h4><ul><li>Adaptimmune Therapeutics (<a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a> <font color='red'>-5.1%</font>) <a href=\"https://seekingalpha.com/pr/16778362-adaptimmune-therapeutics-plc-prices-public-offering-american-depositary-shares\" target=\"_blank\">prices </a>its public offering of 14.3M American Depositary Shares (ADSs) at $4.20 per ADS. Underwriters over-allotment is an additional 2.145M ADSs. Net proceeds will fund pipeline development and general corporate purposes. Closing date is March 27.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252756\" data-linked=\"Adaptimmune prices equity offering at $4.20; shares off 5%\" data-tweet=\"$ADAP - Adaptimmune prices equity offering at $4.20; shares off 5% https://seekingalpha.com/news/3252756-adaptimmune-prices-equity-offering-4_20-shares-off-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3252756-adaptimmune-prices-equity-offering-4_20-shares-off-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252755\" data-ts=\"1490192079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTI\" target=\"_blank\">APTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252755-apptiominus-4_15-amid-ipo-lock-up-expiry\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apptio -4.15% amid IPO lock-up expiry</a></h4><ul><li>On a gradual reduction since going public last September (<font color='red'>-48%</font>), Apptio declines to new lows as <a href=\"http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=11077533#D76087DS1A_HTM_ROM76087_3\" target=\"_blank\">31.285M</a> previously lock-up restricted Class B common stock&nbsp;shares, 84% of total shares outstanding, become <a href=\"http://www.nasdaq.com/markets/ipos/company/apptio-inc-763438-81568\" target=\"_blank\">available for trade</a>.</li><li>Apptio (NASDAQ:<a href='https://seekingalpha.com/symbol/APTI' title='Apptio'>APTI</a>) $11.78.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252755\" data-linked=\"Apptio -4.15% amid IPO lock-up expiry\" data-tweet=\"$APTI - Apptio -4.15% amid IPO lock-up expiry https://seekingalpha.com/news/3252755-apptiominus-4_15-amid-ipo-lock-up-expiry?source=tweet\" data-url=\"https://seekingalpha.com/news/3252755-apptiominus-4_15-amid-ipo-lock-up-expiry\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252748\" data-ts=\"1490191176\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTL\" target=\"_blank\">VTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252748-vital-therapies-prices-equity-offering-shares-off-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vital Therapies prices equity offering; shares off 8%</a></h4><ul><li>Vital Therapies (<a href='https://seekingalpha.com/symbol/VTL' title='Vital Therapies, Inc.'>VTL</a> <font color='red'>-8.2%</font>) <a href=\"https://seekingalpha.com/pr/16778292-vital-therapies-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 8.75M shares of common stock at $4.00. Underwriters over-allotment is an additional ~1.3M shares. Closing date is March 27. Net proceeds will fund the continued development of the ELAD System, working capital and general corporate purposes.</li><li>Yesterday's close was $4.25.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252748\" data-linked=\"Vital Therapies prices equity offering; shares off 8%\" data-tweet=\"$VTL $IMUX - Vital Therapies prices equity offering; shares off 8% https://seekingalpha.com/news/3252748-vital-therapies-prices-equity-offering-shares-off-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3252748-vital-therapies-prices-equity-offering-shares-off-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252749\" data-ts=\"1490191080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252749-nike-analysts-defend-ratings-after-disappointing-forecast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike analysts defend ratings after disappointing forecast</a></h4><ul><li>Nike (<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='red'>-5.9%</font>) plunges more than 5% at the open following its <a href=\"https://seekingalpha.com/news/3252581-nike-beats-0_15-revenue-line\" target=\"_blank\">mixed FQ3 results</a> but offering a <a href=\"https://seekingalpha.com/news/3252585-nike-minus-1_6-percent-posting-line-revenue-growth-q3\" target=\"_blank\">weaker than expected forecast</a> of worldwide future orders; analyst ratings on the stock appear unchanged, at least so far:</li><li>Jefferies: Buy, $75 price target. Not concerned by futures data as it is &ldquo;increasingly less correlated with total growth.\"</li><li>Telsey Advisory:&nbsp;Outperform, PT&nbsp;$66. While the path remains &ldquo;choppy,&rdquo; NKE is gaining traction and heading in the right  direction, which should drive better operating results and stock price.</li><li>Susquehanna:&nbsp;Positive, PT raised to $65 from $64. NKE pulled &ldquo;one of its many levers&rdquo; to deliver EPS upside and &ldquo;has a host  of additional levers at its disposal&rdquo; to drive EPS upside going forward.</li><li>Stifel: Buy, but PT dropped to $66 from $68. North America remains challenged, forex pressures to EPS are projected  to stiffen in FY 2018, masking expectations for constant currency progress  in reported EPS.</li><li>Piper Jaffray:&nbsp;Neutral, PT $51. Q3 EPS beat was of &ldquo;low quality,&rdquo; futures continue to decelerate Q/Q, stark Q/Q slowdown in  digital to 18% from 46% likely from rapid shift in North America and China toward Adidas.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252749\" data-linked=\"Nike analysts defend ratings after disappointing forecast\" data-tweet=\"$NKE - Nike analysts defend ratings after disappointing forecast https://seekingalpha.com/news/3252749-nike-analysts-defend-ratings-after-disappointing-forecast?source=tweet\" data-url=\"https://seekingalpha.com/news/3252749-nike-analysts-defend-ratings-after-disappointing-forecast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252747\" data-ts=\"1490190814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCXI\" target=\"_blank\">CCXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252747-chemocentryxs-avacopan-orphan-drug-for-c3g-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ChemoCentryx&#39;s avacopan an Orphan Drug for C3G; shares ahead 3%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16778093-chemocentryx-receives-fda-orphan-drug-designation-avacopan-treatment-debilitating-kidney\" target=\"_blank\">designates </a>ChemoCentryx's (<a href='https://seekingalpha.com/symbol/CCXI' title='ChemoCentryx'>CCXI</a> <font color='green'>+3%</font>) avacopan an Orphan Drug for the treatment of C3 glomerulopathy (C3G), a severe kidney disease characterized by protein deposits from the body's complement system into and around the organ's filtration units (glomeruli) that leads to kidney failure.</li><li>Small molecule avacopan arrests the kidney damage associated with C3G by inhibiting the complement C5a receptor which plays a key role in the inflammatory process. An efficacy study will be initiated next quarter.</li><li>Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252747\" data-linked=\"ChemoCentryx&#39;s avacopan an Orphan Drug for C3G; shares ahead 3%\" data-tweet=\"$CCXI - ChemoCentryx&#39;s avacopan an Orphan Drug for C3G; shares ahead 3% https://seekingalpha.com/news/3252747-chemocentryxs-avacopan-orphan-drug-for-c3g-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3252747-chemocentryxs-avacopan-orphan-drug-for-c3g-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252744\" data-ts=\"1490189811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIRI\" target=\"_blank\">SIRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252744-sirius-xmminus-1_8-barclays-heads-to-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sirius XM -1.8% as Barclays heads to sidelines</a></h4><ul>   <li>Sirius XM (NASDAQ:<a href='https://seekingalpha.com/symbol/SIRI' title='Sirius XM Holdings Inc.'>SIRI</a>) has come out of the open <font color='red'>1.8% lower</font> as Barclays goes to Equal Weight from a previous Overweight stance.</li>    <li>Analyst Kannan Venkateshwar has set a $4.90 price target, 5.6% lower than yesterday's close.</li>    <li>Valuation has much to do with the neutral stance, as the stock has outperformed the market by some 18% over the past several months, he notes.</li>    <li>M&amp;A can't be ruled out, he says, but the likelihood of a deal for Pandora has been tamped down in recent weeks.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252744\" data-linked=\"Sirius XM -1.8% as Barclays heads to sidelines\" data-tweet=\"$SIRI - Sirius XM -1.8% as Barclays heads to sidelines https://seekingalpha.com/news/3252744-sirius-xmminus-1_8-barclays-heads-to-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3252744-sirius-xmminus-1_8-barclays-heads-to-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252739\" data-ts=\"1490188745\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIN\" target=\"_blank\">WIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252739-windstreamminus-5_6-downgraded-goldman-dims-on-wirelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Windstream -5.6%, downgraded as Goldman dims on wirelines</a></h4><ul>   <li>Windstream Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a>) is <font color='red'>5.6% lower</font> in premarket trading after being reinstated at Sell by Goldman Sachs, newly taking a dim view on wireline firms.</li>    <li>It earlier <a href=\"https://seekingalpha.com/news/3252685-frontier-minus-5-percent-goldman-cuts-sell\" target=\"_blank\">downgraded Frontier to Sell</a> (FTR is <font color='red'>off 8.9%</font> in early going), and has reinstated CenturyLink at Sell as well (<a href='https://seekingalpha.com/symbol/CTL' title='CenturyLink, Inc.'>CTL</a> is <font color='red'>0.5% lower</font>).</li>    <li>As with its stance on Frontier, Goldman believes Windstream has thin dividend coverage. It's looking to declines in revenues as well as free cash flow.</li>    <li>The sector as a whole faces hot competition and declines in broadband subscribers this year, the firm says.</li>    <li>Goldman's price target on Windstream is $4.50, implying 30% downside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252739\" data-linked=\"Windstream -5.6%, downgraded as Goldman dims on wirelines\" data-tweet=\"$WIN $WINMQ $CTL - Windstream -5.6%, downgraded as Goldman dims on wirelines https://seekingalpha.com/news/3252739-windstreamminus-5_6-downgraded-goldman-dims-on-wirelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3252739-windstreamminus-5_6-downgraded-goldman-dims-on-wirelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252734\" data-ts=\"1490188389\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252734-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul> <li>SHLD <font color='red'>-12%</font> on doubts over maintaining 'going-concern'.</li><li><a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='red'>-8%</font> on analyst downgrade.</li><li><a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a> <font color='red'>-8%</font> on $75M secondary offering.</li><li><a href='https://seekingalpha.com/symbol/VSR' title='Versar, Inc'>VSR</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='red'>-6%</font> on Q3 earnings.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3252734\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$SHLDQ $FTR $RGNX - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3252734-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3252734-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252732\" data-ts=\"1490188242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLPG\" target=\"_blank\">GLPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252732-galapagos-initiates-early-stage-study-on-cf-candidate-glpg3067-earns-7_5m-milestone-from\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galapagos initiates early-stage study on CF candidate GLPG3067, earns $7.5M milestone from AbbVie</a></h4><ul><li>Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos'>GLPG</a>) perks up&nbsp;<font color='green'>1%</font>&nbsp;premarket, albeit on only 896 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/16777755-galapagos-initiates-phase-1-study-novel-cf-potentiator-glpg3067\" target=\"_blank\">announcement </a>that it has launched a Phase 1 study of cystic fibrosis &#40;CF&#41; candidate GLPG3067 triggering a $7.5M milestone payment from collaboration partner AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>).</li><li>The single center study will assess GLPG3067's safety, tolerability and pharmacokinetics in 48 healthy volunteers in Belgium. The last part of the study will assess the combination of GLPG3067 and GLPG2222. Top-line data will be submitted for presentation at a future medical conference.</li><li>The companies are working on combination therapy for CF that addresses three complementary components. They are currently testing potentiator GLPG2451 and corrector GLPG2222 in healthy volunteers and plan to add corrector GLPG2737 to make a triple combination. GLPG3067 is also a potentiator.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252732\" data-linked=\"Galapagos initiates early-stage study on CF candidate GLPG3067, earns $7.5M milestone from AbbVie\" data-tweet=\"$GLPG $GLPG $ABBV - Galapagos initiates early-stage study on CF candidate GLPG3067, earns $7.5M milestone from AbbVie https://seekingalpha.com/news/3252732-galapagos-initiates-early-stage-study-on-cf-candidate-glpg3067-earns-7_5m-milestone-from?source=tweet\" data-url=\"https://seekingalpha.com/news/3252732-galapagos-initiates-early-stage-study-on-cf-candidate-glpg3067-earns-7_5m-milestone-from\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252731\" data-ts=\"1490188163\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252731-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a> <font color='green'>+20%</font> on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color='green'>+17%</font> on analyst upgrade.</li><li><a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+13%</font> on approval of EU patent for its drug delivery technology. </li><li><a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+12%</font> on FDA designating Annamycin an Orphan Drug for the treatment of AML.</li><li><a href='https://seekingalpha.com/symbol/BEBE' title='bebe stores, inc.'>OTC:BEBE</a> <font color='green'>+12%</font>.</li><li><a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/RUN' title='Sunrun'>RUN</a> <font color='green'>+6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3252731\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$DLTH $IDRA $PULM - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3252731-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3252731-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252722\" data-ts=\"1490187227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMY-OLD\" target=\"_blank\">IMMY-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252722-imprimis-pharma-inks-3_1m-direct-capital-raise-shares-ease-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imprimis Pharma inks $3.1M direct capital raise; shares ease 8% premarket</a></h4><ul><li>Thinly traded nano cap Imprimis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMY-OLD' title='Imprimis Pharmaceuticals, Inc.'>IMMY-OLD</a>) is off&nbsp;<font color='red'>8%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16778024-imprimis-pharmaceuticals-raise-3_1-million-registered-direct-offering\" target=\"_blank\">announcement </a>that it has entered into agreements with two investors for the direct placement of 1.312M shares of common stock at $2.40. Closing date is March 27.</li><li>Yesterday's close was $2.42.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252722\" data-linked=\"Imprimis Pharma inks $3.1M direct capital raise; shares ease 8% premarket\" data-tweet=\"$IMMY-OLD - Imprimis Pharma inks $3.1M direct capital raise; shares ease 8% premarket https://seekingalpha.com/news/3252722-imprimis-pharma-inks-3_1m-direct-capital-raise-shares-ease-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3252722-imprimis-pharma-inks-3_1m-direct-capital-raise-shares-ease-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252718\" data-ts=\"1490186715\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252718-moleculins-annamycin-orphan-drug-for-aml-shares-ahead-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin&#39;s Annamycin an Orphan Drug for AML; shares ahead 16% premarket</a></h4><ul><li>Thinly traded nano cap Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) perks up&nbsp;<font color='green'>16%</font>&nbsp;premarket on robust volume in response to the FDA designating <a href=\"http://www.moleculin.com/technology/annamycin/\" target=\"_blank\">Annamycin </a>an Orphan Drug for the treatment of relapsed/refractory acute myeloid leukemia &#40;AML&#41;.</li><li>Annamycin is a member of the anthracycline class of chemotherapeutic agents (includes doxorubicin). Its value proposition is less cardiotoxicity and greater ability to overcome multidrug resistance mechanisms.</li><li>Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252718\" data-linked=\"Moleculin&#39;s Annamycin an Orphan Drug for AML; shares ahead 16% premarket\" data-tweet=\"$MBRX - Moleculin&#39;s Annamycin an Orphan Drug for AML; shares ahead 16% premarket https://seekingalpha.com/news/3252718-moleculins-annamycin-orphan-drug-for-aml-shares-ahead-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3252718-moleculins-annamycin-orphan-drug-for-aml-shares-ahead-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252717\" data-ts=\"1490186486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252717-fedex-now-up-nearly-3-post-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx now up nearly 3% post-earnings</a></h4><ul><li>Shares knee-jerked lower yesterday evening after the company missed FQ3 estimates by a wide margin, but<a href=\"http://www.cnbc.com/2017/03/22/fedex-misses-on-earnings-but-sees-higher-margins-ahead.html\" target=\"_blank\"> management painted an</a> optimistic picture on the earnings call (<a href=\"https://seekingalpha.com/article/4056983-fedexs-fdx-ceo-fred-smith-q3-2017-results-earnings-call-transcript\" target=\"_blank\">call transcript</a>)</li><li>CEO Fred Smith says he expects ground segment margins of 15%+ in the current quarter, and sees margins, cash flows, and returns as all gaining over the coming years.</li><li>As for Amazon's move into the delivery business .... \"Let me just say&nbsp;that Amazon is a longstanding customer of ours,\" says FedEx's (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>)&nbsp;Raj Subramaniam.</li><li>Shares&nbsp;<font color='green'>+2.7%</font>&nbsp;premarket</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252594-fedex-minus-3_75-percent-earnings-miss\" target=\"_blank\">FedEx -3.75% after earnings miss</a> (March 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3252717\" data-linked=\"FedEx now up nearly 3% post-earnings\" data-tweet=\"$FDX - FedEx now up nearly 3% post-earnings https://seekingalpha.com/news/3252717-fedex-now-up-nearly-3-post-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3252717-fedex-now-up-nearly-3-post-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252716\" data-ts=\"1490186088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNXL\" target=\"_blank\">UNXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252716-unipixelplus-25-pre-market-enters-multi-year-arrangement-major-u-s-pc-manufacturer-for-xtouch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UniPixel +25% pre-market, enters multi-year arrangement with major U.S. PC manufacturer for XTouch sensor supply</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/16778027-unipixel-signs-long-term-agreement-major-u-s-based-pc-maker-supply-xtouch-sensors\" target=\"_blank\">cooperation</a> stipulates rolling forecasts be provided by the unspecified U.S.-based partner for use by UniPixel in allocating manufacturing capacity. Purchases are agreed to be made, on a best-efforts basis, in line with forecasts supplied.</li><li>Mutual sharing of product development roadmaps, engagement through meetings and requests by the customer for exclusive early access to select UniPixel technologies are further components of the deal.</li><li>UniPixel (NASDAQ:<a href='https://seekingalpha.com/symbol/UNXL' title='Uni-Pixel, Inc.'>UNXL</a>) $0.95.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252716\" data-linked=\"UniPixel +25% pre-market, enters multi-year arrangement with major U.S. PC manufacturer for XTouch sensor supply\" data-tweet=\"$UNXL - UniPixel +25% pre-market, enters multi-year arrangement with major U.S. PC manufacturer for XTouch sensor supply https://seekingalpha.com/news/3252716-unipixelplus-25-pre-market-enters-multi-year-arrangement-major-u-s-pc-manufacturer-for-xtouch?source=tweet\" data-url=\"https://seekingalpha.com/news/3252716-unipixelplus-25-pre-market-enters-multi-year-arrangement-major-u-s-pc-manufacturer-for-xtouch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252705\" data-ts=\"1490185370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252705-valeant-completes-refinancing-transactions-adds-flexibility-to-credit-agreements-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant completes refinancing transactions, adds flexibility to credit agreements; shares ahead 1% premarket</a></h4><ul><li>Valeant Pharmaceuticals (VRX) has <a href=\"https://seekingalpha.com/pr/16777604-valeant-completes-refinancing-transactions\" target=\"_blank\">closed its refinancing transactions</a>, including its offering of $1.25B aggregate principal amount of 6.50% senior notes due 2022, $2.0B aggregate principal amount 7.00% senior notes due 2024 and borrowing ~$3B via new term loans maturing in 2022.</li><li>Net proceeds, together with cash on hand, will fund the repayment of all term loans under its credit facility maturing in 2018, 2019 and 2020, $350M of borrowings under its credit revolver and $1.1B of its 6.75% senior notes due 2018.</li><li>In addition, the company has amended its existing credit agreements to remove financial maintenance covenants from the term loans, modify the financial maintenance covenants under the revolver and institute certain other amendments.</li><li>Chairman and CEO Joseph C. Papa says, \"Upon closing these transactions, the issuance of $1.25 billion and $2.0 billion of senior secured notes due 2022 and 2024, respectively, and the tender for $1.1 billion of our &nbsp;Senior Notes due 2018, the amount of our debt maturing prior to 2020 will be&nbsp;substantially reduced. In addition, the amended terms of the credit agreement will provide us with improved operating flexibility and a greater margin of safety with respect to financial covenants. Together, these transactions, coupled with our ongoing asset sale process, will enable Valeant to focus on driving the fundamental operating performance of its various businesses. We want to thank the lenders, investors and other financial institutions that supported us in the completion of this important initiative.\"</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252705\" data-linked=\"Valeant completes refinancing transactions, adds flexibility to credit agreements; shares ahead 1% premarket\" data-tweet=\"$BHC - Valeant completes refinancing transactions, adds flexibility to credit agreements; shares ahead 1% premarket https://seekingalpha.com/news/3252705-valeant-completes-refinancing-transactions-adds-flexibility-to-credit-agreements-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3252705-valeant-completes-refinancing-transactions-adds-flexibility-to-credit-agreements-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252702\" data-ts=\"1490184754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DEA\" target=\"_blank\">DEA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252702-easterly-government-properties-down-2_4-on-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Easterly Government Properties down 2.4% on capital raise</a></h4><ul><li>The company <a href=\"https://seekingalpha.com/pr/16777968-easterly-government-properties-announces-pricing-common-stock-offering\" target=\"_blank\">sold 4.3M shares of</a> common stock at $19 each. The underwriters have a greenshoe option for another 645K shares at that price.</li><li><a href='https://seekingalpha.com/symbol/DEA' title='Easterly Government Properties'>DEA</a><font color='red'> -2.4%</font>&nbsp;premarket to $19.25.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252702\" data-linked=\"Easterly Government Properties down 2.4% on capital raise\" data-tweet=\"$DEA - Easterly Government Properties down 2.4% on capital raise https://seekingalpha.com/news/3252702-easterly-government-properties-down-2_4-on-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3252702-easterly-government-properties-down-2_4-on-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252699\" data-ts=\"1490184746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PERY\" target=\"_blank\">PERY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252699-perry-ellis-lower-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Perry Ellis lower post Q4 results</a></h4><ul>     <li>Perry Ellis (NASDAQ:<a href='https://seekingalpha.com/symbol/PERY' title='Perry Ellis International Inc.'>PERY</a>)&nbsp;reports revenue declined 3.3% on a constant currency basis in <a href=\"https://seekingalpha.com/pr/16777885-perry-ellis-international-reports-fourth-quarter-full-fiscal-2017-results\" target=\"_blank\">Q4</a>.</li>     <li>Royalty income slipped 3.3% to $8.61M.</li>     <li>Adjusted gross margin rate improved 140 bps to 37.2%.</li>     <li>SG&amp;A expense rate fell 250 bps to 31.6%.</li>     <li>Adjusted EBITDA margin rate expanded 240 bps to 8.4%.</li>     <li>Inventories -17.2% Y/Y to $151.25M.</li>     <li><b>FY2018 Guidance</b>: Revenue: $870M to $880M; Adjusted EPS: $2.07 to $2.17.</li>     <li>PERY&nbsp;<font color='red'>-3.16%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252699\" data-linked=\"Perry Ellis lower post Q4 results\" data-tweet=\"$PERY - Perry Ellis lower post Q4 results https://seekingalpha.com/news/3252699-perry-ellis-lower-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3252699-perry-ellis-lower-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252700\" data-ts=\"1490184380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252700-novartis-serelaxin-flunks-late-state-heart-failure-study-shares-ease-fraction-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novartis&#39; serelaxin flunks late-state heart failure study; shares ease a fraction premarket</a></h4><ul><li>Novartis (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) is off a fraction premarket on light volume in response to its <a href=\"https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-rlx030-serelaxin-patients-acute-heart\" target=\"_blank\">announcement </a>that a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT01870778?term=NCT01870778&amp;rank=1\" target=\"_blank\">RELAX-AHF-2</a>, evaluating RLX030 (serelaxin) in patients with acute heart failure failed to achieve the primary endpoint of a statistically valid reduction in cardiovascular death through day 180 or reduced worsening heart failure through day 5 when added to standard therapy.</li><li>Global Head, Drug Development and Chief Medical Officer Vas Narasimhan says, \"We are disappointed this study did not confirm the efficacy of RLX030 in acute heart failure, especially given the urgent need for effective new treatments for this condition. We will continue to further analyze the data to better understand and learn from these results as well as evaluate next steps for the overall program.\"</li><li>RLX030, a relaxin receptor agonist, is a recombinant form of the naturally occurring hormone human relaxin-2. It is present in both men and women, but elevated in pregnant women and is thought to help the body cope with additional cardiovascular demands during pregnancy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252700\" data-linked=\"Novartis&#39; serelaxin flunks late-state heart failure study; shares ease a fraction premarket\" data-tweet=\"$NVS - Novartis&#39; serelaxin flunks late-state heart failure study; shares ease a fraction premarket https://seekingalpha.com/news/3252700-novartis-serelaxin-flunks-late-state-heart-failure-study-shares-ease-fraction-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3252700-novartis-serelaxin-flunks-late-state-heart-failure-study-shares-ease-fraction-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252696\" data-ts=\"1490183980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAL\" target=\"_blank\">UAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252696-seeing-pricing-cracks-morgan-stanley-cuts-view-on-airlines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seeing &#39;pricing cracks,&#39; Morgan Stanley cuts view on airlines</a></h4><ul><li>Analyst Rajeev Lalwani sees domestic capacity rising 4-5%, or twice real GDP growth, noting United's (NASDAQ:<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a>) announcement of a doubling in expected supply growth, and the potential for additions at American Airlines (NASDAQ:<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a>), Delta (NYSE:<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a>), and Southwest (NYSE:<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a>).</li><li>He cuts his sector view to inline from attractive, and downgrades American to equalweight from overweight. AAL&nbsp;<font color='red'>-1.1%</font>&nbsp;premarket.</li><li>He prefers higher quality names like Alaska Air (NYSE:<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a>), Delta, and Southwest.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3252696\" data-linked=\"Seeing &#39;pricing cracks,&#39; Morgan Stanley cuts view on airlines\" data-tweet=\"$UAL $UAL $AAL - Seeing &#39;pricing cracks,&#39; Morgan Stanley cuts view on airlines https://seekingalpha.com/news/3252696-seeing-pricing-cracks-morgan-stanley-cuts-view-on-airlines?source=tweet\" data-url=\"https://seekingalpha.com/news/3252696-seeing-pricing-cracks-morgan-stanley-cuts-view-on-airlines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252695\" data-ts=\"1490183633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADAP\" target=\"_blank\">ADAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252695-adaptimmune-readies-equity-offering-shares-ease-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adaptimmune readies equity offering; shares ease 3% premarket</a></h4><ul><li>Adaptimmune Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a>) <a href=\"https://seekingalpha.com/pr/16777622-adaptimmune-therapeutics-plc-proposes-public-offering-american-depositary-shares\" target=\"_blank\">initiates </a>a public offering of American Depositary Shares. Price, volume and terms have yet to be announced.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;premarket on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252695\" data-linked=\"Adaptimmune readies equity offering; shares ease 3% premarket\" data-tweet=\"$ADAP - Adaptimmune readies equity offering; shares ease 3% premarket https://seekingalpha.com/news/3252695-adaptimmune-readies-equity-offering-shares-ease-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3252695-adaptimmune-readies-equity-offering-shares-ease-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252692\" data-ts=\"1490183254\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252692-shires-shp655-fast-trackd-for-rare-enzyme-deficiency-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire&#39;s SHP655 Fast Track&#39;d for rare enzyme deficiency; shares up 1% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16777907-shire-receives-fda-fast-track-designation-recombinant-adamts13-shp655-treatment-hereditary\" target=\"_blank\">designates </a>Shire plc's (NASDAQ:<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a>) SHP655 for Fast Track review for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura in patients with a deficiency in an enzyme called ADAMTS13. The disorder, affecting 3,000 - 4,000 people worldwide, is characterized by life-threatening clotting in the microvasculature.</li><li>SHP655 is a recombinant ADAMTS13. A Phase 3 study will be initiated soon.</li><li>Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application &#40;NDA&#41;.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252692\" data-linked=\"Shire&#39;s SHP655 Fast Track&#39;d for rare enzyme deficiency; shares up 1% premarket\" data-tweet=\"$SHPG - Shire&#39;s SHP655 Fast Track&#39;d for rare enzyme deficiency; shares up 1% premarket https://seekingalpha.com/news/3252692-shires-shp655-fast-trackd-for-rare-enzyme-deficiency-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3252692-shires-shp655-fast-trackd-for-rare-enzyme-deficiency-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252687\" data-ts=\"1490182625\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WGO\" target=\"_blank\">WGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252687-on-winnebagos-fq2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Winnebago&#39;s FQ2</a></h4><ul>     <li>Winnebago (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>) reports revenue rose 64.2% in <a href=\"https://seekingalpha.com/pr/16777870-winnebago-industries-announces-second-quarter-fiscal-2017-results\" target=\"_blank\">FQ2</a> due to higher&nbsp;shipments of 3.6% in motorized units and 467.2% in towables.</li>     <li>Motorized revenue dropped 3% to $198.94M.</li>     <li>Towable revenue grew 735.6% to $171.6M.</li>     <li>Gross margin improved 210 bps to 13.3% driven by the favorable inclusion of Grand Design products within the overall sales mix.</li>     <li>Operating margin rate increased 170 bps to 7.7%.</li>     <li>Total motor homes deliveries +3.6% Y/Y to 2,107.</li>     <li>Total towable deliveries +467.2% Y/Y to 5,411.</li>     <li>Dealer inventory: Motorized +7% to 5,068; Towables +299.7% to 9,216.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3252687\" data-linked=\"More on Winnebago&#39;s FQ2\" data-tweet=\"$WGO - More on Winnebago&#39;s FQ2 https://seekingalpha.com/news/3252687-on-winnebagos-fq2?source=tweet\" data-url=\"https://seekingalpha.com/news/3252687-on-winnebagos-fq2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252685\" data-ts=\"1490181874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTR\" target=\"_blank\">FTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252685-frontierminus-5-goldman-cuts-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frontier -5% as Goldman cuts to Sell</a></h4><ul><li>The market appears to be pricing in a 50% dividend cut, but analyst Brett Feldman doesn't see this as enough to drive long-term deleveraging and thinks the entire payout could be suspended.</li><li>He downgrades Frontier (NYSE:<a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a>) to Sell, and halves his price target to $1.50 (<font color='red'>36% downside</font>).</li><li>He reinstates Windstream (NASDAQ:<a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a>) with a Sell rating and Street-low $4.50 price target, noting expectations of revenue and free cash flow declines and thin dividend coverage.</li><li>CenturyLink (NYSE:<a href='https://seekingalpha.com/symbol/CTL' title='CenturyLink, Inc.'>CTL</a>) is also reinstated with a Sell, with PT trimmed to $19 from $21.</li><li>Source: Bloomberg</li><li>FTR&nbsp;<font color='red'>-5.1%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3252685\" data-linked=\"Frontier -5% as Goldman cuts to Sell\" data-tweet=\"$FTR $FTR $WINMQ - Frontier -5% as Goldman cuts to Sell https://seekingalpha.com/news/3252685-frontierminus-5-goldman-cuts-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3252685-frontierminus-5-goldman-cuts-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3252681\" data-ts=\"1490180996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CALA\" target=\"_blank\">CALA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3252681-calithera-prices-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calithera prices equity offering</a></h4><ul><li>Calithera Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a>) <a href=\"https://seekingalpha.com/pr/16777892-calithera-biosciences-inc-prices-public-offering-6830-000-shares-common-stock\" target=\"_blank\">prices </a>its public offering of 6.83M shares of common stock at $10.25 per share. Underwriters over-allotment is an additional 1,024,500 shares. Closing date is March 27.</li><li>Yesterday's close was $10.55.</li></ul><div class=\"tiny-share-widget\" data-id=\"3252681\" data-linked=\"Calithera prices equity offering\" data-tweet=\"$CALA - Calithera prices equity offering https://seekingalpha.com/news/3252681-calithera-prices-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3252681-calithera-prices-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":61,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}